|Treatments:||Chemotherapy, Immunotherapy||Hospital:||Städtisches Klinikum|
Patients: This phase III study involved one hundred forty-nine women with previously untreated ovarian cancer. All were between the ages of 18 and 65.
Treatment: The women received either standard chemotherapy (paclitaxel and carboplatin) or high dose paclitaxel, carboplatin, and peripheral stem cell support. Peripheral stem cell support involves removing these cells from patients before chemotherapy, and then replacing them afterwards. All patients also received the chemotherapy melphalan.
Toxicity: One treatment-related death occurred, due to hemorrhagic shock. Grade 3/4 infection was reported. Other toxicities included nausea, stomatitis, sensory/neurological, and oesophagitis.
Results: The median overall survival was 62.8 months for the standard treatment group, and 54.4 months for the patients receiving the high-dose treatment.
Support: This study was supported by funds from Amgen and Bristol-Myers Squibb.
Correspondence: Dr. Volker Mobus